Intellia Therapeutics Investor Presentation — October 2018

Document content

Q3 2018 Earnings and

Corporate Developments

Intellia Therapeutics Legal Disclaimers

This presentation contains “forward -looking statements” of Intellia Therapeutics, Inc. (“ Intellia ”) within the meaning of the Private Securities Litigation

Reform Act of 1995. These forward -looking statements include, but are not limited to, express or implied statements regarding Intellia’s ability to

advance and expand the CRISPR/Cas9 technology to develop into human therapeutic products, as well as our CRISPR/Cas9 intellec tual property

portfolio; our ability to achieve stable or effective genome editing; our ability to administer multiple doses of our CRISPR/ Cas9 product candidates; the

potential timing and advancement of our preclinical studies, including continuing non -human primate studies for our T ransthyreti n Amyloidosis (“ATTR”)

program and other programs (such as alpha -1 antitrypsin deficiency (AATD)), and clinical trials; the timing and potential achiev ement of milestones to

advance our pipeline including filing INDs; our ability to replicate results achieved in our preclinical studies, including t hose in our ATTR, AATD and

Wilms’ T umor 1 (WT1) programs, in any future studies, including human clinical trials; the potential development of our propr ietary lipid nanoparticle

(LNP) -adeno -associated virus (AAV) hybrid delivery system to advance our complex genome editing capabilities; the potential dev elopment of other in

vivo orex vivo cell therapeutics of all types, and those targeting WT1 in particular, using CRISPR/Cas9 technology; our ability to conduct s uccessful

Investigational New Drug (“IND”) -enabling studies of a lead ATTR development candidate and subsequently submitting an IND applic ation that will be

accepted by the regulatory agencies; our intent to present additional data for organs beyond the liver, additional insertion/ repair data, and preclinical data

in support of our first ex vivo programs on immuno -oncology and autoimmune/inflammation indications during 2018 or thereafter; our ability to advance a

development candidate for an in vivo second indication by late 2018 or thereafter; the intellectual property position and strategy of Intellia’s licensors or

other parties from which it derives rights, as well as third -parties and competitors; actions by government agencies; our growth as a company and the

anticipated contribution of the members of our board of directors and our executives to our operations and progress; the impa ct of our collaborations on

our development programs; the potential timing of regulatory filings regarding our development programs; the potential commer cialization opportunities,